Description
Drostanolone Propionate (Masteron P, Masteron) is a 2α-methylated dihydrotestosterone derivative with propionic acid esterification. The structural modification at C2 makes the substance resistant to 5α-reduction (to DHT) and to aromatization (to estradiol).
Per study reports Masteron binds to the androgen receptor and additionally has weak anti-estrogen action as competitive antagonist at the estrogen receptor. This dual action makes Masteron the preferred compound in recreational research practice for cutting phases where both muscle preservation and dry appearance matter.
The propionate ester form has a half-life of about 2-3 days. Research protocols require injections every 1-2 days for stable plasma levels. In practice Masteron P is often combined with other propionate esters (Test P, Tren A) for synchronized injection frequencies.
Clinically Drostanolone was used in the 1960s-1980s for breast cancer treatment as adjuvant therapy. The anti-estrogen action was the relevant mechanism in this setting.
Known effects in studies: low hepatotoxicity (no 17α-methyl), no water retention, mild androgenic effects (acne, hair loss with predisposition), moderate HPG suppression. Lipid profile worsening documented.
Drostanolone is on the WADA banned list.
You can order Drostanolone Propionate as an oily injection solution in 10-pack at 100mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Drostanolone Propionate is considered milder tolerated compared to anabolic heavyweights - the effects described in the literature are manageable, but the DHT derivative remains an effective anabolic with a clear risk profile.
Documented in studies and the application literature:
- No aromatization: the 2-alpha-methylated DHT derivative is resistant to aromatization, estrogen-mediated effects and water retention are not documented. A weak anti-estrogen residual action is described.
- Androgenic effects: as a DHT derivative, mild androgenic effects such as acne and accelerated hair loss with genetic predisposition are documented.
- Suppression of endogenous production: Masteron moderately suppresses the HPG axis. Reduced endogenous testosterone production is documented, a test base is customary in research practice.
- Cardiovascular: the literature describes a worsening of the lipid profile, cardiac effects with long-term use are documented. Hepatotoxicity is low because there is no 17-alpha-methyl group.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Effect of drostanolone propionate on the binding of oestradiol and dihydrotestosterone by normal and malignant target tissues - European Journal of Cancer 1977: receptor-binding study of drostanolone propionate at estradiol and DHT targets.
- Antitumor efficacy of 2alpha-methyl dihydrotestosterone propionate in advanced breast cancer - Cancer 1962: historical oncology study on the efficacy of drostanolone propionate in advanced breast cancer.
- Drostanolone and norethisterone in disseminated breast cancer - Drug and Therapeutics Bulletin 1969: clinical evaluation of drostanolone propionate in metastatic breast cancer.
- Identification of drostanolone and 17-methyldrostanolone metabolites produced by cryopreserved human hepatocytes - Steroids 2009: hepatic metabolism of drostanolone characterized in human hepatocyte cultures.
- Intracerebroventricular Self-Administration of Commonly Abused Anabolic-Androgenic Steroids in Male Hamsters - Behavioral Neuroscience 2005: behavioral pharmacology study on the reinforcement profile of drostanolone and other AAS.
